EU CHMP To Review July Rejection Of Drugs For Schizophrenia, Metastatic Breast Cancer

The EMA’s CHMP is this week hearing oral evidence on two products it turned down in July – for schizophrenia and metastatic breast cancer – as well as on other drugs for multiple myeloma and multiple sclerosis.

Review
The CHMP is reviewing its initial rejections of two new drugs.

During its meeting this week, the European Medicines Agency’s scientific committee, the CHMP, is due to re-examine approval applications for two products that it rejected earlier this year: Vanda Pharmaceuticals Inc.’s Fanaptum (iloperidone) for schizophrenia and Nektar Therapeutics’ Onzeald (etirinotecan pegol) for breast cancer with brain metastases.

In rejecting Fanaptum at its meeting in July, the CHMP said the product’s effectiveness was “modest” and that it started...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet